Investigational Drug Information for Neridronic acid
✉ Email this page to a colleague
What is the development status for investigational drug Neridronic acid?
Neridronic acid is an investigational drug.
There have been 4 clinical trials for Neridronic acid.
The most recent clinical trial was a Phase 3 trial, which was initiated on May 30th 2018.
The most common disease conditions in clinical trials are Complex Regional Pain Syndromes, Syndrome, and Reflex Sympathetic Dystrophy. The leading clinical trial sponsors are Grünenthal GmbH and [disabled in preview].
There are zero US patents protecting this investigational drug and zero international patents.
Summary for Neridronic acid
| US Patents | 1,471 |
| International Patents | 14,284 |
| US Patent Applications | 5,302 |
| WIPO Patent Applications | 135 |
| Japanese Patent Applications | 984 |
| Clinical Trial Progress | Phase 3 (2018-05-30) |
| Vendors | 43 |
Recent Clinical Trials for Neridronic acid
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS) | Grünenthal GmbH | Phase 3 |
| Efficacy and Safety of Intravenous Neridronic Acid in CRPS | Grünenthal GmbH | Phase 3 |
| Safety of Intravenous Neridronic Acid in CRPS | Grünenthal GmbH | Phase 3 |
Clinical Trial Summary for Neridronic acid
Top disease conditions for Neridronic acid
Top clinical trial sponsors for Neridronic acid
US Patents for Neridronic acid
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Neridronic acid | ⤷ Sign Up | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | ⤷ Sign Up |
| Neridronic acid | ⤷ Sign Up | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | ⤷ Sign Up |
| Neridronic acid | ⤷ Sign Up | Use of inhibitors of Bruton'S tyrosine kinase (Btk) | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Sign Up |
| Neridronic acid | ⤷ Sign Up | Use of inhibitors of Bruton's tyrosine kinase (Btk) | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Sign Up |
| Neridronic acid | ⤷ Sign Up | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | ANTECIP BIOVENTURES II LLC (New York, NY) | ⤷ Sign Up |
| Neridronic acid | ⤷ Sign Up | Inhibition of hypoxia-inducible factor activity with carica papaya extracts | The Regents of the University of California (Oakland, CA) Universiti Putra Malaysia (Selangor Darul Ehsan, MY) | ⤷ Sign Up |
| Neridronic acid | ⤷ Sign Up | Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators | Reset Therapeutics, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Neridronic acid
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Neridronic acid | Australia | AU2006213610 | 2025-02-10 | ⤷ Sign Up |
| Neridronic acid | Canada | CA2596845 | 2025-02-10 | ⤷ Sign Up |
| Neridronic acid | Denmark | DK1851340 | 2025-02-10 | ⤷ Sign Up |
| Neridronic acid | European Patent Office | EP1851340 | 2025-02-10 | ⤷ Sign Up |
| Neridronic acid | Hong Kong | HK1115165 | 2025-02-10 | ⤷ Sign Up |
| Neridronic acid | Japan | JP2008535474 | 2025-02-10 | ⤷ Sign Up |
| Neridronic acid | Japan | JP5031587 | 2025-02-10 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
